| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 8 |
| 1 | ETOPOSIDE | 8 |
| 2 | CYTARABINE | 5 |
| 3 | MELPHALAN HYDROCHLORIDE | 5 |
| 4 | CYCLOPHOSPHAMIDE | 4 |
| 5 | CYCLOPHOSPHAMIDE FOR INJECTION | 4 |
| 6 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 4 |
| 7 | DEXAMETHASONE | 4 |
| 8 | DEXAMETHASONE 1.5 MG | 4 |
| 9 | METHYLPREDNISOLONE | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IDECABTAGENE VICLEUCEL | 1 | 0.0008 |
| 1 | MITOXANTRONE HYDROCHLORIDE | 4 | 0.0006 |
| 2 | MELPHALAN HYDROCHLORIDE | 5 | 0.0002 |
| 3 | CILTACABTAGENE AUTOLEUCEL | 1 | 0.0002 |
| 4 | ETOPOSIDE | 8 | 0.0001 |
| 5 | CISPLATIN | 8 | 0.0001 |
| 6 | CLADRIBINE | 1 | 0.0001 |
| 7 | BLEOMYCIN SULFATE | 1 | 0.0001 |
| 8 | CYTARABINE | 5 | 0.0001 |
| 9 | NIRAPARIB | 1 | 0.0000 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 8 |
| 1 | Topoisomerase Inhibitor [EPC] | 8 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 5 |
| 3 | Alkylating Drug [EPC] | 4 |
| 4 | CD20-directed Cytolytic Antibody [EPC] | 4 |
| 5 | Corticosteroid [EPC] | 4 |
| 6 | Thalidomide Analog [EPC] | 3 |
| 7 | BCL-2 Inhibitor [EPC] | 2 |
| 8 | Janus Kinase Inhibitor [EPC] | 1 |
| 9 | Kinase Inhibitor [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Topoisomerase Inhibitor [EPC] | 8 | 0.0001 |
| 1 | BCL-2 Inhibitor [EPC] | 2 | 0.0000 |
| 2 | Platinum-based Drug [EPC] | 8 | 0.0000 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 5 | 0.0000 |
| 4 | Alkylating Drug [EPC] | 4 | 0.0000 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 4 | 0.0000 |
| 6 | Purine Antimetabolite [EPC] | 1 | 0.0000 |
| 7 | Proteasome Inhibitor [EPC] | 1 | 0.0000 |
| 8 | Janus Kinase Inhibitor [EPC] | 1 | 0.0000 |
| 9 | Thalidomide Analog [EPC] | 3 | 0.0000 |